Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.

Marasca, Claudio; Ruggiero, Angelo; Megna, Matteo; Annunziata, Maria Carmela; Fabbrocini, Gabriella

Marasca, Claudio; Ruggiero, Angelo; Megna, Matteo; Annunziata, Maria Carmela; Fabbrocini, Gabriella.

Marasca C; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, Italy.
Ruggiero A; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, Italy.
Megna M; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, Italy.
Annunziata MC; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, Italy.
Fabbrocini G; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Naples, Italy.

J Dermatolog Treat ; 33(1): 592, 2022 Feb.

Article in English | MEDLINE | ID: covidwho-260580

Subject(s)

Biological Products; COVID-19; Hidradenitis Suppurativa; Biological Products/therapeutic use; Hidradenitis Suppurativa/drug therapy; Humans; Referral and Consultation; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Biological Products / Hidradenitis Suppurativa / COVID-19 Limits: Humans Language: English Journal: J Dermatolog Treat Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: 09546634.2020.1769828

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google